Stem cells are resistant to TRAIL receptor-mediated apoptosis

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 11-12, 2009, Pages 4409-4414

  Szegezdi, Eva ^a   O'Reilly, Aoife ^a   Davy, Yeung ^b   Vawda, Reaz ^b   Taylor, Deanna L ^b   Murphy, Mary ^a   Samali, Afshin ^a   Mehmet, Huseyin ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Bone marrow derived adult MSC; Caspases; D269H E195R; DR4; DR5; Foetal mesenchymal stem cells (fMSC); TRAIL; Umbilical cord matrix stem cells (UCMS); Wharton's Jelly stem cells

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CYTOLOGY; DRUG EFFECT; HUMAN; METABOLISM; STEM CELL; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; HUMANS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; STEM CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77951179467     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00522.x     Document Type: Article

References (18)

1. Walczak H, Miller RE, Ariail K. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999, 5:157-63.
2. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999, 11:255-60.
3. Young LS, Searle PF, Onion D. Viral gene therapy strategies: from basic science to clinical application. J Pathol. 2006, 208:299-318.
4. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004, 36:568-84.
5. Studeny M, Marini FC, Champlin RE. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62:3603-8.
6. Studeny M, Marini FC, Dembinski JL. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004, 96:1593-603.
7. Aboody KS, Bush RA, Garcia E. Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE. 2006, 1:e23.
8. Nakamura K, Ito Y, Kawano Y, Kurozumi K. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004, 11:1155-64.
9. Campagnoli C, Roberts IA, Kumar S. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001, 98:2396-402.
10. Gotherstrom C, Ringden O, Tammik C. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol. 2004, 190:239-45.
11. Speert H. Obstetric-gynecologic eponyms; Thomas Wharton and the jelly of the umbilical cord. Obstet Gynecol. 1956, 8:380-2.
12. Mitchell KE, Weiss ML, Mitchell BM. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells. 2003, 21:50-60.
13. O'Donoghue K, Fisk NM. Fetal stem cells. Best Pract Res Clin Obstet Gynaecol. 2004, 18:853-75.
14. Wang HS, Hung SC, Peng ST. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells. 2004, 22:1330-7.
15. Kennea NL, Stratou C, Naparus A. Functional intrinsic and extrinsic apoptotic pathways in human fetal mesenchymal stem cells. Cell Death Differ. 2005, 12:1439-41.
16. van der Sloot AM, Tur V, Szegezdi E. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA. 2006, 103:8634-9.
17. Holohan C, Szegezdi E, Ritter T. Cytokine-induced beta-cell apoptosis is NO-dependent, mitochondria-mediated and inhibited by BCL-X(L). J Cell Mol Med. 2008, 12:591-606.
18. Szegezdi E, Herbert KR, Kavanagh ET. Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion via regulation of Bim. J Cell Mol Med. 2008, 12:2482-96.